Member Info for Early_Bird

trades are buys

you are prob right, personally I think Cathal has played an absolute blinder shifting to Pharma, many wouldnt have the balls. Also noted is that we old Fastnet SHs still have an equal share of the Fatnet Hydrocarbons holding company which Cathal also hinted at in the video he aims on floating again next year.

Cathal got asked pretty much this question near the end of the video link a few posts below. His response being along the lines of newsflow to start end of summer in order to keep strong newsflow momentum going. So we are reaching the sharp end now IMO. Certainly I don’t think management were too bothered about initial SP movement in the first 3 months for a number of reasons. Firstly the structure of the deal with the warrant holders always meant SP would be struggling initially, I think the boards number one aim was to get the Birken and Som takeovers successfully completed under the new company of Amryt publically listed on AIM. Once this was done, a huge first tick, enabled the platform to go ahead with their plan. All the big holders are locked in for 18 months. These guys know the score and know the SP movement will come down the line when P3 trials start hence I don’t think they were too bothered seeing it slip in first month or two. There is a clear end game here in my opinion. All the directors are concert parties with Birken shareholders as collectively hold over 30% limit hence cannot add any more at the moment even if they would like to. You know as much as me but I think the quality of the BOD here along with their skin in the game mean they aren’t here just to play the typical game of sitting on their salaries whilst diluting SHs in to oblivion (which is what 90% on aim do).

Also calling me a patronising prick is strong when you are the one sparking up your first post on here with "quit your BS" that's a pretty arrogant tone so naturally I'm just giving you some of your own.

If nasdaq listing is mentioned this year then you dissapear matey... never once have said it will be in next release but I can say im 99% sure we will hear something on it this year. I have been here for a good few years in fastnet oil and gas then fastnet equity... actually got a lot of stick from one poster for mentioning that a biopharma rto was on the cards 6 months before it happened... not seen that poster since oddly enough. Now you... calling me a BSer is pretty strong considering wouldnt you say?

the Nasdaq application process takes 6-9months which is why I say we should be hearing news on this soon.

Amazes me how lazy some people are and need to be spoon fed like a baby! Come on equitrader... buck your ideas up fella

Hmmm that's a strong comment from a joker with just 274 posts to their name! willing top bet I'm *slightly* more researched than you here. No offence. Do some basic research. If you had then youd be reading all my past posts where I have referenced posts to videos. Given that one of the directors in the company has stated in an interview broadcast that they "almost certainly hope to be fully listed on nasdaq by summer next year" Reference here: https://www.youtube.com/watch?v=3xvETqoMrwQ Scroll to 7:30mins in..... Its no coincidence they have Joe Wiley CEO here who was director at Nasdaq listed Innocoll so knows all the protocol very well. £10million cash, no debt.... enough cash for P3 trial completion so think you may have your wires crossed somewhat.

due this month I believe so not long to wait here for the next update at the very least as a footnote attached to them or as a separate release. News on: Prelim P3 trials commencing Imlan marketting update Possible Nasdaq listing application

also the only other competitor (that was bought for $842m on commencement of its P3 trials) has had its trials postponed... Can only be a good thing for AMYT as outlined by the Shorecapital House Broker note

no worries, it seems going off peers that takeover/buyout offers start coming in at commencement of P3. The valuations achieved are mind boggling... many hundres of millions to billions. Quite exciting give P3 are due to commence here soon.

Beaufort dated 8th Aug

" In May 2016, Pfizer purchased Anacor Pharmaceuticals for $5.2 billion in an all cash deal to get access to their Eczema gel which is in a phase three trial at the moment. Amryt has been tracking this company for some time now as Anacor�s lead product is also a topical skincare gel aimed at the pediatric market and just over 3 years ago their market cap would have been sub $150m when the shares traded at $3.19 a share as opposed to around $100 today. This demonstrates the really exciting potential of Amryt as its pharmaceutical product Episalvan is of interest to many of the multinational pharma companies as it has already been approved by the European Medicines Agency earlier this year and will be commencing sales shortly. Furthermore, as soon as the Amryt Phase III trial of Episalvan for Epidermolysis Bullosa gets under way then Amryt is going to be of even more interest to these multinational pharmaceutical companies. "

very strong buying this morning 4 x 50k buys isnt your average PI. RSI cooled off ready for the next push up ready for newsflow by the looks of it

Back from my hols and good to see this level holding I think its safe to say this is the new floor. Not long now until newsflow starts here

agreed

Hold 50% of the company... just researching atm. Thats huge skin ni the game!

Very solid here.. no debt too...

Great post and totally agree. I think more are starting to cotton on here now that news flow rich period is approaching. Cathal Friel sunk £1m of his own hard earned paying a premium to the 24p IPO of 32p + locked in for 18 months as all directors are. Another big tick for me is that the management here are not just Pharma boffins but they are business minded dragons with direct contacts to the biggest players in the industry so you can bet discussions between Shire and Amyt are already going on in the background. £500m to a £45billion Market cap company is chicken feed esp when trying to dominate the Orphan drug space and they are having stiff competition from Sanoffi to dominate the space currently. Bidding war? Fully cashed up for completion of P3 trials also key for me. People will trade this one for 10% but just does not interest me with the huge potential on offer. Potential here is more than any other share ive come across on AIM over the next 12 months. Ive been holding this for 18months+ loyal fastnet holder here and very excited I think the next 12 will be very special.

Highest since IPO 3 months ago. Very bullish.